EyePoint Inc

Financials

Cash from operating activities -14.44 M-50.1 M-65 M1.88 M-126.23 M-240.11 M -240.11 M Cash from investing activities -362 K-33.12 M-17.27 M-3.31 M-219.35 M68.58 M 68.58 M Cash from financing activities 37.49 M216.9 M-690 K187.07 M164.02 M173.65 M 173.65 M Free cash flow -14.8 M-50.25 M-67.16 M-1.61 M-130.28 M-243.39 M -243.39 M

EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.

EYPT

Financials

EyePoint Inc

Haberler

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

EyePoint Pharmaceuticals RBC Konferansı: Oftalmolojide Stratejik İlerleme

Guggenheim, Duravyu güvenlik verileri sonrası EyePoint hisse notunu korudu

Guggenheim reiterates EyePoint stock rating on Duravyu safety data

EyePoint hissesi için Mizuho Outperform notunu korudu

EyePoint stock rating maintained at Outperform by Mizuho

H.C. Wainwright, EyePoint hissesi için hedef fiyatı 30 dolara yükseltti

H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress

EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT)

EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript

Chardan, EyePoint hissesi için hedef fiyatı 29 dolara yükseltti

Chardan raises EyePoint stock price target to $29 on cash position